Mohamed H Omer
Overview
Explore the profile of Mohamed H Omer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
46
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ahmad O, Omer M, Janjua M, Alayary I, Fathala A, Alsergani H, et al.
ESC Heart Fail
. 2024 Sep;
11(6):4348-4359.
PMID: 39219298
Aims: Cardiac amyloidosis (CA) is a potentially fatal multisystemic disease that remains significantly underdiagnosed, particularly in the Middle East. This study aims to evaluate the prevalence and clinical characteristics of...
2.
Omer M, Shafqat A, Ahmad O, Nadri J, Alkattan K, Yaqinuddin A
J Clin Med
. 2024 Apr;
13(8).
PMID: 38673612
Systemic lupus erythematosus (SLE) is the prototypical systemic autoimmune disorder. Kidney involvement, termed lupus nephritis (LN), is seen in 40-60% of patients with systemic lupus erythematosus (SLE). After the diagnosis,...
3.
Salama H, Omer M, Shafqat A, Binahmed A, Alghamdi G, Saeed M, et al.
BMC Palliat Care
. 2024 Feb;
23(1):60.
PMID: 38419053
Background: Several studies emerging from developed countries have highlighted a significant number of potentially avoidable emergency department (ED) visits by cancer patients during the end-of-life period. However, there is a...
4.
Shafqat A, Khan S, Omer M, Niaz M, Albalkhi I, Alkattan K, et al.
Front Aging Neurosci
. 2023 Dec;
15:1281581.
PMID: 38076538
Cellular senescence is a biological aging hallmark that plays a key role in the development of neurodegenerative diseases. Clinical trials are currently underway to evaluate the effectiveness of senotherapies for...
5.
Mohty D, Omer M, Ahmad O, Alayary I, Alzahrani T, Damy T, et al.
Front Cardiovasc Med
. 2023 Nov;
10:1265681.
PMID: 37953763
No abstract available.
6.
Shafqat A, Omer M, Albalkhi I, Alabdul Razzak G, Abdulkader H, Abdul Rab S, et al.
Front Immunol
. 2023 Oct;
14:1254310.
PMID: 37828990
Post-acute COVID-19 sequelae, commonly known as long COVID, encompasses a range of systemic symptoms experienced by a significant number of COVID-19 survivors. The underlying pathophysiology of long COVID has become...
7.
Omer M, Shafqat A, Ahmad O, Alkattan K, Yaqinuddin A, Damlaj M
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760519
Bispecific T-cell engagers (BiTEs) and bispecific antibodies (BiAbs) have revolutionized the treatment landscape of hematological malignancies. By directing T cells towards specific tumor antigens, BiTEs and BiAbs facilitate the T-cell-mediated...
8.
Shafqat A, Omer M, Ahmed E, Mushtaq A, Ijaz E, Ahmed Z, et al.
Front Immunol
. 2023 Jul;
14:1200941.
PMID: 37520562
This review focuses on the immunosuppressive effects of tumor angiogenesis and coagulation on the tumor microenvironment (TME). We summarize previous research efforts leveraging these observations and targeting these processes to...
9.
Shafqat A, Omer M, Ahmed E, Mushtaq A, Ijaz E, Ahmed Z, et al.
Front Immunol
. 2023 Jul;
14:1252998.
PMID: 37520538
[This corrects the article DOI: 10.3389/fimmu.2023.1200941.].
10.
Salama H, Eldadah S, Omer M, Alhejazi A, Bin Dayil L, Almozaini A, et al.
Leuk Res
. 2023 May;
130:107316.
PMID: 37245332
Background: The outcomes of Pediatric acute lymphoblastic leukemia (ALL) have improved dramatically whereas outcomes for ALL amongst adolescents and young adults (AYA) have lagged behind. The introduction of pediatric-like regimens...